Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Grape King Bio Ltd (1707.TW)
Taoyuan City, TW
Grape King Bio Ltd. is a Taiwanese enterprise specializing in the production and distribution of a diverse array of health-focused items, encompassing pharmaceuticals, traditional remedies, nourishing beverages, and dietary supplements. Its market presence spans Taiwan, mainland China, and various international regions. The company engages with customers through multiple operational avenues, including multi-level marketing channels, conventional distribution networks, and a significant original design and equipment manufacturing (ODM/OEM) division. Among its extensive product range are various mushroom mycelium derivatives, notably ganoderma lucidum, agaricus blazei, antrodia cinnamomea, cordyceps sinensis, and coriolus versicolor. Additionally, it formulates and supplies probiotics featuring strains like enterococcus, bifidobacterium, lactobacillus, pediococcus, streptococcus, saccharomyces, and clostridium, alongside a selection of enzyme products. Beyond its own brand, Grape King Bio offers comprehensive contract services, such as original equipment manufacturing (OEM), original design manufacturing (ODM), custom formulation development, dedicated research and development support, and the provision of raw materials. Established in 1969, the firm maintains its corporate headquarters in Taoyuan City, Taiwan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.36% | -3.11% | -7.63% | -11.38% | -15.50% | -13.83% | -19.85% | -37.71% | -34.73% | -43.81% | +1,454.92% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-8.1% Q1'26: +1.1% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-16.2% Q1'26: -15.7% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+12.0% Q1'26: +45.7% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+20.9% ★ Q1'26: +14.7% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+21.7% ★ Q1'26: +13.2% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+51.8% Q1'26: +63.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.08× ★ Q1'26: 0.16× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
7.25B
est: 7.23B (+0.2%)
|
9.19B
est: 9.20B (-0.1%)
|
9.39B
est: 9.39B (+0.0%)
|
9.18B
est: 9.25B (-0.7%)
|
9.24B
est: 9.21B (+0.3%)
|
9.17B
est: 9.13B (+0.5%)
|
9.80B
est: 9.79B (+0.1%)
|
10.39B
est: 10.32B (+0.7%)
|
10.64B
est: 10.86B (-2.0%)
|
11.16B
est: 11.16B (0.0%)
|
10.25B
est: 10.25B (0.0%)
|
11.19B
11.19B – 11.19B
+9.2% YoY
|
| EBITDA |
2.06B
est: 2.13B (-3.6%)
|
2.55B
est: 2.71B (-5.8%)
|
2.65B
est: 2.77B (-4.4%)
|
2.70B
est: 2.73B (-1.1%)
|
2.77B
est: 2.72B (+1.9%)
|
2.80B
est: 2.69B (+3.9%)
|
2.85B
est: 2.89B (-1.4%)
|
3.14B
est: 3.04B (+3.2%)
|
3.12B
est: 3.11B (+0.4%)
|
3.16B
est: 3.20B (-1.2%)
|
2.69B
est: 2.94B (-8.4%)
|
3.21B
3.21B – 3.21B
+9.2% YoY
|
| EBIT |
1.81B
est: 1.82B (-0.3%)
|
2.23B
est: 2.31B (-3.3%)
|
2.25B
est: 2.36B (-4.4%)
|
2.35B
est: 2.32B (+1.1%)
|
2.34B
est: 2.31B (+0.9%)
|
2.39B
est: 2.29B (+4.3%)
|
2.42B
est: 2.46B (-1.8%)
|
2.68B
est: 2.59B (+3.3%)
|
2.66B
est: 2.62B (+1.8%)
|
2.65B
est: 2.69B (-1.3%)
|
2.14B
est: 2.47B (-13.3%)
|
2.70B
2.70B – 2.70B
+9.2% YoY
|
| Net Income |
1.05B
est: 1.24B (-15.3%)
|
1.30B
est: 1.47B (-11.8%)
|
1.35B
est: 1.42B (-4.8%)
|
1.30B
est: 1.44B (-9.8%)
|
1.94B
est: 1.41B (+37.8%)
|
1.90B
est: 1.39B (+36.7%)
|
1.95B
est: 1.34B (+45.1%)
|
2.17B
est: 1.45B (+49.6%)
|
1.45B
est: 2.17B (-33.1%)
|
1.45B
est: 2.11B (-31.5%)
|
1.22B
est: 2.16B (-43.7%)
|
2.24B
2.24B – 2.24B
+3.3% YoY
|
| SGA |
4.47B
est: 3.89B (+15.1%)
|
5.57B
est: 4.94B (+12.7%)
|
5.45B
est: 5.05B (+8.0%)
|
4.79B
est: 4.97B (-3.6%)
|
5.04B
est: 4.95B (+1.8%)
|
4.98B
est: 4.91B (+1.5%)
|
5.25B
est: 5.26B (-0.2%)
|
5.64B
est: 5.55B (+1.7%)
|
5.75B
est: 5.78B (-0.5%)
|
5.87B
est: 5.94B (-1.2%)
|
5.28B
est: 5.45B (-3.2%)
|
5.95B
5.95B – 5.95B
+9.2% YoY
|
| EPS |
8.07
est: 8.32 (-3.0%)
|
9.82
est: 9.86 (-0.4%)
|
10.03
est: 9.52 (+5.4%)
|
9.57
est: 9.63 (-0.6%)
|
14.27
est: 9.43 (+51.3%)
|
13.92
est: 9.30 (+49.7%)
|
13.20
est: 9.00 (+46.6%)
|
14.65
est: 9.72 (+50.7%)
|
9.81
est: 9.59 (+2.3%)
|
9.79
est: 9.33 (+4.9%)
|
8.22
est: 9.56 (-14.0%)
|
9.88
9.88 – 9.88
+3.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-05 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-04 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-30 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-29 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-28 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-27 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree Emerging Markets SmallCap Dividend UCITS ETF DGSD.L | 0.06% | 24.4K | 0.54% |
| 2 | WisdomTree Emerging Markets SmallCap Dividend Fund DGS | 0.04% | 758.3K | 0.58% |
| 3 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.04% | 143.4K | 0.72% |
| 4 | iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L | 0.03% | 19.9K | 0.74% |
| 5 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.03% | 181.3K | 0.65% |
| 6 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.02% | 71.1K | 0.74% |
| 7 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.02% | 113.7K | 0.55% |
| 8 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.01% | 14.3K | 0.42% |
| 9 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.01% | 1.35M | 0.06% |
| 10 | Dimensional - Emerging Markets Value ETF DFEV | 0.01% | 132.4K | 0.46% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bing-Jyun Cuei | Chief Legal Officer | — | male |
| Chung-Chi Hung | Chief Internal Auditor | — | — |
| Du-Sheng Wang | Director of Administration Division | — | male |
| Nick Hung | Accounting Supervisor, Chief Financial Officer & Corporate Governance Officer | — | male |
| Sheng-Lin Tseng | Chairman & GM | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 1707.TW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
